D
espite advances in the diagnosis and treatment of cardiometabolic diseases, the genetic basis of atherosclerosis and glucometabolic traits remains only partially understood. Multiple genome-wide association studies (GWAS) have begun to elucidate the genetics of complex cardiometabolic diseases, yet the majority of its heritability remains unknown. 1, 2 Initial GWAS evolved to HapMap-based metaanalyses focused on detecting common variation at the population level. More recently, imputation, using data from the 1000 Genomes project and exome sequencing projects, has allowed capture of additional information on low-frequency and rare variation. 3, 4 Gains in our understanding of complex traits through these approaches suggest that multiple variants with small effect sizes drive complex diseases and that a variety of unbiased, targeted, and functional strategies are required to elucidate the full genetic contributions to cardiometabolic disease. 1, 5 
Clinical Perspective on p 258
The chemokine receptors CCR2, CCR5, and CX3CR1 are potential modifiers of both atherosclerosis and glucometabolic traits. 6 These receptors are expressed on leukocyte populations and vascular cells in both homeostatic and inflammatory states. Mice lacking any of these receptors have attenuated atherosclerosis with combinations of multiple receptor knockouts demonstrating a more pronounced phenotype, supporting the idea that these chemokine pathways act in an independent and additive manner. 7 In vitro studies have demonstrated that cells carrying the human CX3CR1 variants V249I and T280M have a reduced number of fractalkine binding sites and reduced affinity for fractalkine on peripheral blood mononuclear cells. 8, 9 Before the GWAS era, a series of small case-control studies provided inconsistent and at times conflicting data for association of these single nucleotide polymorphisms (SNPs) with coronary artery disease (CAD), myocardial infarction (MI), and glucometabolic traits. [9] [10] [11] Similarly, a handful of small studies have explored the relationship of the CCR2 V64I variant to CAD with inconsistent findings. 12, 13 With the advent of large-scale human genetic databases, we are now able to ascertain whether the findings observed in knockout mouse models are transferable to humans. This question is of broad and general importance to translational studies of atherosclerosis particularly for innate and adaptive immune pathways where there has been limited clinical translation despite convincing evidence of disease modulation in mouse models.
We thus interrogated large contemporary data sets of common, low-frequency, and rare genetic variation at CCR2, CCR5, and CX3CR1 for CAD, MI, and glucometabolic traits. Briefly, our focus was first on the V249I and T280M CX3CR1 and V64I CCR2 variants previously reported to associate with cardiometabolic traits. We then interrogated all common and low-frequency variation in and around each gene. Finally, when available, we examined in composite rare exonic variants in each gene for trait association. Specifically, we accessed the CARDIoGRAMplusC4D (Coronary ARtery DIsease Genome wide Replication and Meta-analysis [CARDIoGRAM] plus The Coronary Artery Disease [C4D] Genetics) and Myocardial Infarction Genetics (MIGen) and CARDIoGRAM Exome array metaanalyses for common and low-frequency variants in CAD as well as the Exome Sequencing Project (ESP) Early Onset Myocardial Infarction (EOMI) consortium data for rare variation in MI. We then performed a focused interrogation of summary data from the MAGIC, DIAGRAM, GLGC, and GIANT consortia GWAS meta-analyses, which assess common variation in subjects with a range of glucometabolic phenotypes. Pakistan Risk of Myocardial Infarction Study (PROMIS) case-control studies were leveraged to explore low-frequency and common variation in CCR2, CCR5, and CX3CR1 in a South Asian population in which CAD, MI, and type II diabetes mellitus (DM) are enriched.
Methods

Studies of CAD and MI
We leveraged the sample sizes and statistical power of the CARDIoGRAMplusC4D, MIGen, and CARDIoGRAM Exome array, and ESP EOMI studies, all described in detail in the Data Supplement. 1, 2, 4, [14] [15] [16] The CARDIoGRAMplusC4D meta-analysis includes merged data from the classic CARDIoGRAM and C4D GWAS, consolidating genetic information from 60 801 CAD and MI case subjects and 123 504 control subjects of mixed ancestry across 48 studies. 1, 2, 5, 14 Genotypes were imputed using the 1000 Genomes phase 1, version 3 reference panel (Table 1) . 3 Variants were filtered on a minor allele frequency (MAF) >0.5%. Genomic control was applied before inclusion in the meta-analysis, and subsequently a second correction for genomic control was repeated after inclusion in the meta-analysis. Association testing was performed using logistic regression on additive, recessive, and dominant models of disease susceptibility. Studies were combined using a fixed-effects, inversevariance-weighted meta-analysis. Summary-level data from additive models were extracted for variants within 5000 bps of the start and end positions of CCR2, CCR5, and CX3CR1 (Table I in the Data  Supplement) .
The MIGen and CARDIoGRAM Exome array consortia metaanalyzed data from 19 studies totaling 42 335 MI case subjects and 78 240 control subjects of European ancestry (Table 1) all genotyped on the Illumina HumanExome BeadChip (Illumina, San Diego, CA). 16 The individual studies performed logistic regression on an additive model using the principal components of ancestry as covariates, and study level data were combined using an inversevariance-weighted meta-analysis. Variants were restricted to those with a MAF ≥0.01%. Summary-level data were retrieved for polymorphic exomic variants in CCR2, CCR5, and CX3CR1. Although 8 studies in the data set overlapped completely or partially with the CARDIoGRAMplusC4D meta-analysis, the focus of the MIGen and CARDIoGRAM Exome array consortia differs substantively from that of CARDIoGRAMplusC4D given its specific focus on low-frequency variation.
The ESP EOMI consortium merged exome sequence data from 14 studies, 11 initial studies and 3 follow-up studies, totaling 4703 case subjects and 5090 control subjects of European ancestry (Table 1) . 4, 15 Association testing for genetic variation in CCR2, CCR5, and CX3CR1 was performed by aggregating a burden of rare variants (SNPs and indels present at a MAF <1%) for each gene. The predicted functional impact of each rare variant was annotated using 7 algorithms, [25] [26] [27] [28] [29] [30] and we tested for an association separately for 3 classes of variants: (1) nonsynonymous variants, (2) disruptive variants (nonsense, splice-site, and indel frameshift variants), and (3) deleterious variants, defined as disruptive variants in combination with missense variants damaging by at least 5 of the 7 aforementioned algorithms.
PROMIS is a retrospective case-control study of subjects with an acute first MI in urban Pakistan. 17, 18 Samples were genotyped on the Illumina 660 and Illumina 770 arrays and imputed using the 1000 by guest on July 8, 2017 http://circgenetics.ahajournals.org/ Downloaded from genomes phase I integrated reference panel (March 2012). 3 Individual tests for association were performed on variants with MAF >1% adjusting for the first 4 principal components. Summary-level data were examined for SNPs within 5000 bps of CCR2, CCR5, and CX3CR1 on 9058 MI case subjects and 8378 control subjects (Table 1; Table  I in the Data Supplement). Although PROMIS data are nested in full within the CARDIoGRAMplusC4D database, we focused on it separately to interrogate ethnic-specific differences potentially obscured by the larger CARDIoGRAMplusC4D cohort.
Studies of Glucometabolic Traits
Detailed descriptions of these meta-analyses have been published and our specific approach detailed in Table 1 and the Data Supplement. Briefly, we accessed the DIAGRAM, GIANT, GLGC, and MAGIC consortia meta-analyses to ascertain the association of chemokine receptor variation with glucometabolic traits in European subjects. [19] [20] [21] [22] [23] [24] These resources contain genetic information on a range of glucometabolic traits including type II DM, BMI, weight-to-hip ratio, lipid and lipid-related traits, and glucose metabolism ( Table 1) . The PROMIS MI resource is described above. 17, 18 In addition to MI, association tests were performed for type II DM and lipid levels (Table 1) , and summary data extracted for SNPs within 5000 bps of CCR2, CCR5, and CX3CR1.
Statistical Analysis
For our chemokine receptor focus, unadjusted summary association P values were Bonferroni corrected for the number of SNPs tested in each study (Table 1) . For the ESP EOMI consortium, unadjusted P values are reported. Linkage disequilibrium (LD) for European subjects was taken from the 1000 genomes phase 3 reference panel available through the 1000 genomes browser.
3 LD for South Asian subjects was calculated from the 1000 genomes phase 3, version 5 SAS reference panel using PLINK version 1.07 (http://pngu.mgh.harvard.edu/purcell/plink/). 31 LD structure was visualized in Haploview separately for the 2 populations 32 with gene structure visualized through the Integrative Genomics Viewer 2.3.67.
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To calculate power, risk allele frequencies from CARDIo GRAMplusC4D were tested against a range of risk allele frequency differences under a genome-wide significance threshold of 5×10 −8 . 5 Sample sizes were taken from the CARDIoGRAMplusC4D and PROMIS data sets. The power calculation formula was modified from Skol to incorporate unequal numbers of cases and controls. 
Results
CAD and MI
Common and Low-Frequency Variation in CCR2, CCR5, and CX3CR1 Lacks Association With CAD or MI in Large Predominantly European Ancestry Samples
In the pre-GWAS era, the V249I and T280M variants in CX3CR1 and V64I in CCR2 were ascribed functional effects although found to have conflicting findings for association with CAD. [8] [9] [10] [11] [12] [13] 35 We extracted CAD and MI association P values for these SNPs from the CARDIoGRAMplusC4D and MIGen and CARDIoGRAM Exome array consortia metaanalyses, currently the 2 largest genome-wide resources of CAD and MI. 5, 16 Neither CX3CR1 V249I, CX3CR1 T280M nor CCR2 V64I reached statistical significance in either data set ( Table 2) .
Next, because complete deletion of these chemokine receptor genes in mouse models attenuates atherosclerosis, 7, 36, 37 we more comprehensively surveyed association signals in these loci by examining whether any common or low-frequency SNPs in CCR2, CCR5, or CX3CR1 relate to CAD or MI. To address this, we used the CARDIoGRAMplusC4D 1000 genomes imputed summary data set that contains information on common and lowfrequency variation in 60 801 CAD subjects and 123 504 control subjects. 5 Of the 220 variants interrogated, 5 SNPs in CCR5 and 3 SNPs in CX3CR1 met unadjusted P value significance thresholds of 0.05 but none approximated statistical significance after Bonferroni correction for 220 variants (Table I in the Data Supplement). In the MIGen and CARDIoGRAM Exome array consortia, which contains genetic information for 54 003 low-frequency and common, nonsynonymous, autosomal variants in 120 575 individuals of European ancestry, 42 335 of which have CAD, we extracted association data for the 20 polymorphic SNPs in CCR2, CCR5, and CX3CR1. 16 Three SNPs in CCR5 and 1 in CX3CR1 had unadjusted P<0.05, but none met statistical significance after Bonferroni correction for 20 variants tested (Table II in Rare Variation in CX3CR1, CCR2, and CCR5 and Risk of MI Although large GWAS have systematically evaluated the genetic underpinnings of CAD and MI, they have not been designed to assess trait-associations with rare variants. 1 Using the ESP EOMI data set, which contains information on rare variation in 4703 EOMI case subjects and 5090 control subjects of European American (90.8%) and black (9.2%) descent, we tested the hypothesis that rare exomic variation in CCR2, CCR5, and CX3CR1 modifies the risk of MI. 4 Given the high baseline rate of rare neutral mutations, we systematically aggregated variants using a computational approach in an effort to enrich for pathogenic alleles, deriving sets of nonsynonymous, disruptive, and deleterious variants. Despite this approach, we failed to find an association between rare variants predicted to be functionally deleterious in these chemokine receptors and MI (Table 3) . Although we noted a potential signal in CX3CR1 emerging for disruptive variants damaging by 5 of 7 (P=0.09; odds ratio [OR], 2.71) and 6 of 7 (P=0.13; OR, 2.89) prediction algorithms, this trend lacked consistency across all prediction algorithms (eg, PolyPhen-2: P=0.32; OR, 0.86) and failed to meet significance even without correction for multiple testing.
Association of Common Variation in CX3CR1 With MI in South Asians
To extend our investigation to a distinct ethnic setting in which the risk of MI is increased, we leveraged summarylevel data from the 1000 genomes imputed PROMIS data set, which contains SNPs at a MAF >1% in this Pakistani South Asian sample. 17, 18 The CX3CR1 variant V249I met significance after correction for all SNPs tested, but neither CX3CR1 T280M nor CCR2 V64I were significant in adjusted analyses (Table 2 ). In interrogation of all 181 low-frequency and common SNPs in CCR2, CCR5, and CX3CR1, 5 additional noncoding variants in CX3CR1 were significantly associated with MI after Bonferroni correction ( Table 2; Table III in the Data Supplement). These variants, 4 of which were genotyped, are present in the population at a frequency of 12.8% and in PROMIS are in close LD with one another and with CX3CR1 V249I and T280M (r 2 >0.8; Figure I and Table III in the Data Supplement). Given that these variants are present but not associated with MI in the larger predominantly European ancestry CARDIoGRAMplusC4D meta-analysis, the clinical significance of these associations with respect to MI remains uncertain and requires specific follow-up in larger South Asian cohorts. 
Glucometabolic Traits
Common Variation in CX3CR1, CCR2, and CCR5 Lacks Association With Glucometabolic Traits in Cohorts of European Ancestry Although multiple mouse and human studies have suggested a role for chemokine receptor variation in atherosclerosis, a smaller number of rodent and human studies have implicated the Ccr2, Cx3cr1, and Ccr5 pathways in the development of obesity, insulin resistance, and glucose homeostasis. 6, 11, [38] [39] [40] Therefore, we performed a focused reanalysis of HapMap imputed DIAGRAM, GLGC, GIANT, and MAGIC data sets that contain information on genetic associations for a range of glucometabolic and anthropometric traits. [19] [20] [21] [22] [23] [24] We first interrogated CX3CR1 V249I and T280M as well as CCR2 V64I in GWAS of glucometabolic traits. Neither CX3CR1 variant approximated significance in the HapMap-based GWAS MAGIC, DIAGRAM, GIANT, or GLGC data sets for any phenotype interrogated (Table 4) , whereas CCR2 V64I was not included in these GWAS meta-analyses. We then extended our examination to all available variation at these loci. Of the 53 HapMap-imputed variants within 5000 bps of CCR2, CCR5, and CX3CR1, none approached statistical significance after correction for multiple testing.
Association of Common and Low-Frequency Variation in CX3CR1 With Glucometabolic Traits in South Asians
We interrogated the 1000 genomes imputed PROMIS data set that contains trait-association information on type II DM, high-density lipoprotein-cholesterol, and triglyceride levels on up to 17 348 individuals in this South Asian cohort. Neither CX3CR1 V249I, CX3CR1 T280M, nor CCR2 V64I approximated statistical significance for type II DM or lipid levels (Tables 4). Of the 181 SNPs within 5000 bps of CCR2, CCR5, and CX3CR1, 3 low-frequency, noncoding CX3CR1 variants were associated with type II DM after correction for multiple testing (Table IV in the Data Supplement). These variants, one of which was genotyped, are in close LD with one another (r 2 >0.97) although bore no relationship to the CX3CR1 variants V249I and T280M ( Figure I in the Data Supplement). Of note, 2 of the variants (rs17038647 and rs17038663) are included in the European MAGIC and DIA-GRAM meta-analyses. Although these had a trend toward association with Homeostasis Model Assessment-Insulin resistance (uncorrected P=0.038; P=0.029), a measure of insulin resistance, in MAGIC, these variants were not significant after correction for multiple testing. Furthermore, there was no association between these SNPs and type II DM in DIAGRAM (uncorrected P=0.92; P=0.94). Finally, none of the 181 SNPs were associated with plasma lipid levels in PROMIS.
CARDIoGRAMplusC4D but Not PROMIS Has Ample Power to Detect Genetic Variation at a Range of Allele Frequencies and ORs
To ascertain whether significant variation in PROMIS is likely to represent biologically relevant variation as opposed to false-positive findings, we performed a post hoc power calculation based on the CARDIoGRAMplusC4D and PRO-MIS databases using a range of allele frequencies and allele frequency differences (Table V in the Data Supplement). At each allele frequency surveyed in CARDIoGRAMplusC4D, we had >95% power to detect an allele frequency difference as small as 0.1%. In contrast, in PROMIS, we had 95% power to detect allele frequency differences only when these were >5%. 
Discussion
Experimental and clinical studies have attempted to elucidate the role of several chemokines and their receptors in the development of atherosclerosis and glucometabolic disorders. Rodent studies provide convincing data supporting a role, both independent and additive, for the chemokine receptors CCR2, CCR5, and CX3CR1 in the development of experimental atherosclerosis, insulin resistance, and cardiometabolic disorders through their modulation of monocyte recruitment and macrophage phenotypes. As a paradigm for exploring the consistency of human genetic data with mouse models of disease, we interrogated large contemporary data sets of common, low-frequency, and rare genetic variation in these chemokine receptor genes for association with CAD, MI, and glucometabolic traits. We failed to find evidence of an association between genetic variation in CCR2, CCR5, and CX3CR1 and any of the traits studied in European ancestry data sets. In South Asians, we identified SNPs in CX3CR1 with suggestive MI and type II DM associations, yet these same variants did not meet statistical significance in much larger predominantly European data sets. Our findings exclude clinically meaningful associations with CAD and glucometabolic traits in Europeans but suggest a need for larger studies in South Asians and other ethnicities.
Mouse data suggest a role for CCR2, CCR5, and CX3CR1 in atherogenesis. In hypercholesterolemic, atherosclerosissusceptible apolipoprotein E-deficient mice, combined inhibition of Ccl2, Cx3cr1, and Ccr5, led to abrogation of bone marrow monocytosis and to an additive reduction in circulating monocytes in the setting of persistent hypercholesterolemia. 7 This was associated with a marked and additive 90% reduction in atherosclerosis. Ablation of individual chemokine receptors each modulated specific monocyte subpopulations and had significant but lesser impact on mouse atherosclerosis than combined inhibition. The common CX3CR1 coding polymorphisms V249I and T280M, which are in strong LD, are reported to reduce cellular adhesion in vitro under conditions of physiological shear-stress and to impair chemotaxis and cell signaling. 8 Despite convincing studies in mice and evidence for functional impact of human genetic variation on monocytes, the role of these genes in human atherosclerosis and CAD has not been well established. Many small genetic studies have looked for associations between chemokine receptor polymorphisms and CAD and MI with conflicting results. 9, 10, 41, 42 In the Ludwigshafen Risk of Cardiovascular Health study, a cross-sectional study of 2583 case subjects with angiographically defined CAD and 733 control subjects, neither CX3CR1 T280M nor V249I, was significantly associated with CAD or MI (n=1358 subgroup). 10 This study contrasts with a 7-study meta-analysis of 2000 CAD subjects and 2841 controls in which the V249I-T280M haplotype was found to be protective (OR, 0.81; 95% CI, 0.71-0.92; P=0.001). 42 The common CCR2 variant V64I has been reported to associate with increased risk of early MI although this too has been controversial. 41, 43, 44 Similarly, CCR5delta32 has been linked in small studies to reduced susceptibility to CAD and protection against MI.
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Here, we shed light on this issue by interrogating the largest human data sets of common and low-frequency genetic variation for CAD and MI-the CARDIoGRAMplusC4D GWAS consortium in which we focus on common variation, and the MIGen and CARDIoGRAM Exome array consortia in which our focus is on low-frequency exonic variation. 5, 16 These overlapping data sets contain information on 42 335 and 60 801 CAD subjects and 123 504 and 78 240 control subjects respectively, all of predominantly European descent. First, we examined CX3CR1 V249I, CX3CR1 T280M, and CCR2 V64I given their putative functional effects and purported CAD associations, but failed to identify any significant associations with CAD or MI. Next, we broadened our search to look at all common and low-frequency variation within 5000 bps of these genes. Again, we did not identify any variants significantly associated with CAD or MI.
In the absence of CAD associations for common and low-frequency variants, it remains possible that rare coding variation and mutations in CCR2, CCR5, or CX3CR1 have a clinically important impact on disease. Therefore, we interrogated the ESP EOMI data set that contains exome sequencing data on 4703 EOMI subjects and 5090 control subjects. 4 We hypothesized that rare alleles in aggregate in each gene might contribute to the risk of MI. When T1 allele count testing was applied, no gene-based signal for any of the chemokine receptors deviated from what was expected by chance though larger exome-seq data sets are required to exclude more modest impact of rare variation. 4 Based on mouse models and small human studies, CCR2, CCR5, and CX3CR1 have been implicated in modulating obesity, insulin resistance, and glucose homeostasis. 11, [38] [39] [40] Both CCR2 and CX3CR1 pathways are reported to modulate monocyte recruitment and macrophage phenotypes in adipose. 38, 40, 46 Multiple small studies have examined the association of obesity with the CX3CR1 variants V249I and T280M, demonstrating an association with increased waist circumference, higher levels of Homeostasis Model AssessmentInsulin resistance, and a trend toward association with type II DM and metabolic syndrome.
46,47 Despite these previous trends, we did not find any association between common variation in CCR2, CCR5, or CX3CR1 and any glucometabolic traits in the large GIANT, DIAGRAM, MAGIC, and GLGC GWAS resources.
The burden of CAD and type II DM is increasing at a greater rate in South Asia than in any other global region. 17 Nevertheless, little is known about the genetic determinants of disease in this population. Although PROMIS is contained in full within the CARDIoGRAMplusC4D meta-analysis, we chose to interrogate PROMIS separately given the distinct genetic background and increased risk of coronary heart disease in this Pakistani sample. We focused our initial investigation on the 1000 genomes imputed PROMIS data set that contains genetic information on 9058 subjects with CAD and 10 310 subjects with type II DM. After correction for multiple testing, we identified 6 variants in PROMIS associated with MI, including CX3CR1 V249I, and 3 low-frequency, noncoding variants associated with type II DM. All variants associated with MI were present in the combined CARDIoGRAMplusC4D meta-analysis of CAD, none of which approached statistical significance. Similarly, 2 of the 3 PROMIS DM-associated variants (rs17038647 and rs17038663) were in MAGIC and DIAGRAM, and neither associated with type II DM nor glucose metabolism in these resources.
The significance of these associations with MI and type II DM in South Asians is unclear. In an earlier analysis of PROMIS data, Saleheen et al 18 showed that the genetic determinants of plasma lipid levels in PROMIS were broadly comparable with those of German subjects in the Ludwigshafen Risk of Cardiovascular Health study, yet the allelic frequencies and magnitude of association differed between the 2 ethnic groups. Similar to our analyses, differences were observed between PROMIS and CARDIoGRAMplusC4D in the allele frequencies (Table 4 ; Table III in the Data Supplement) and LD structures ( Figure I in the Data Supplement). Given these ethnic patterns, these CX3CR1 variants may deserve further follow-up in larger South Asian studies although false-positive findings are also possible given smaller sample size in PROMIS.
We illustrate here the challenge of extrapolating mouse models to human disease. Discrepancies may be because of differences in the molecular basis and pathophysiology of disease in mouse models versus humans. Alternatively, true loss-or gain-of-function human mutations may not be present in candidate genes, limiting a direct comparison between mouse genetic models and human genetic data. Molecular and pathophysiological heterogeneity may be of particular concern in studies of innate and adaptive immunity given differences in mouse and human macrophage phenotypes.
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Human and mouse macrophages have distinct patterns of gene expression during trauma, burns, and endotoxemia. 49 It is important to recognize, however, that lack of a human genetic disease association does not exclude the possibility that the gene product may be involved in disease, particularly if loss-or gain-of-function mutations are not present in humans. Nevertheless, in our analyses, this seems less likely because exome sequencing and exome chip analyses did not reveal convincing signals for rare variants in human coronary heart disease.
There are other potential contributors to discrepancies between mouse and human data. First, previous studies in mice and humans had relatively small sample sizes and often lacked correction for multiple testing, raising the possibility of false-positive results. Second, our analyses may be underpowered in non-European ancestry to detect variants of small to moderate effect sizes (Table V in the Data Supplement). Previous analyses in PROMIS, however, have detected many loci with modest effects on MI suggesting that any association signals at CCR2, CCR5, or CX3CR1, if undetected, must be small if present.
This work has several strengths yet questions remain to be addressed. This is the largest systematic interrogation of cardiometabolic phenotypes for genetic variation in CCR2, CCR5, and CX3CR1. Multiple traits were examined, large data sets for common, low-frequency, and rare variants at these loci were available, and multiple ethnicities were included. Yet, we lacked low-frequency and rare variant data for glucometabolic traits, sample sizes for non-European ancestry were modest, and statistical power for detection of rare variant effects in MI cannot exclude small effects of true mutations. We applied Bonferroni correction for multiple testing, yet this assumes independence across SNPs tested, raising the possibility that we could have missed variants with true small effect sizes. This correction, however, is not conservative in terms of the total number of potential genome-wide tests, and we did not correct for the number of traits examined. A sensitivity analysis also excludes significant effects of more distant regulatory variation within 50 000 bps of each gene (data not shown). Suggestive evidence for associations of variants in CX3CR1 with MI and type II DM only within South Asians requires larger follow-up.
In conclusion, in a comprehensive survey of common, low-frequency, and rare CCR2, CCR5, and CX3CR1 genetic variation in cardiometabolic traits across multiple populations, we failed to find evidence of significant associations in predominantly European ancestry. Although CX3CR1 variants were significantly associated with MI and type II DM in PROMIS, these associations were not significant in the larger CARDIoGRAMplusC4D meta-analysis of CAD or in the MAGIC or DIAGRAM meta-analyses of DM and glycemic traits. This suggests ethnic-specific effects or false-positive findings in PROMIS. Despite convincing rodent model data, our findings fail to support a clinically important role for CCR2, CCR5, or CX3CR1 in the pathogenesis of atherosclerosis or glucometabolic traits in populations of European ancestry. 
CLINICAL PERSPECTIVE
In an effort to identify novel therapeutic targets, experimental and clinical studies have attempted to elucidate the role of several chemokines and their receptors in the development of atherosclerosis and glucometabolic disorders. Mouse data have suggested a role for CCR2, CCR5, and CX3CR1 in atherogenesis and glucose metabolism although the role of these genes in human disease has not been well established. We performed a comprehensive survey of common, low-frequency, and rare CCR2, CCR5, and CX3CR1 genetic variation in cardiometabolic traits across multiple populations, including a separate analysis of South Asian subjects, a population enriched for cardiometabolic disease. We failed to find disease associations in large primarily European cohorts. In a South Asian cohort, we identified CX3CR1 variants associated with myocardial infarction and type 2 diabetes mellitus, suggesting ethnic-specific effects or possibly false-positive findings. Our data thus exclude clinically important association of genetic variation in CCR2, CCR5, and CX3CR1 with cardiometabolic traits and suggest the need for further studies to identify whether there are ethnic-specific differences in CX3CR1 that may be relevant to cardiometabolic disease pathogenesis and treatment.
of Myocardial Infarction Study (PROMIS) Consortia*
SUPPLEMENTAL MATERIALS
Supplemental methods:
Studies of coronary artery disease and myocardial infarction:
CARDIoGRAMplusC4D consortium: The details of the CARDIoGRAMplusC4D, 1000 genomes imputed dataset have already been published. 1 In brief, the CARDIoGRAMplusC4D dataset consists of merged data from the classic genome-wide association studies (GWAS)
CARDIoGRAM and C4D, combining genotype information on 60,801 case subjects and 123,504 control subjects from 48 studies then imputed using the 1000 Genomes phase 1, version 3 reference panel. [1] [2] [3] [4] As described, case subjects were defined by an inclusive coronary artery disease (CAD) diagnosis including myocardial infarction (MI), acute coronary syndrome, chronic stable angina, or coronary stenosis >50%. Association data for each contributing study were individually filtered for MAF > 0.5% and an imputation quality metric. For each study, ancestryinformative or other study-specific covariates were included as necessary which was confirmed on submission by review of the study-specific genomic control lambda. Variants that were retained in at least 60% of the studies were submitted for analysis. Following an inverse variance-weighted, fixed-effects meta-analysis, heterogeneity was assessed by Cochran's Q statistic 5 and the I 2 inconsistency index 6 and variants showing marked heterogeneity were reanalyzed using a random-effects model. 7 Overdispersion in the resulting meta-analysis was adjusted for by a second application of the genomic control procedure. 8.6 million single nucleotide polymorphisms (SNPs) and 836,000 insertions/deletions (indels) were included in the analysis. Association testing was performed by logistic regression on additive, recessive, and dominant models of disease susceptibility. Individual studies were combined using a fixedeffects, inverse-variance weighted meta-analysis.
Myocardial Infarction Genetics (MIGen) and CARDIoGRAM Exome consortia: The MIGen
and CARDIoGRAM Exome array consortia consists of merged data from 19 studies totaling 42,335 MI case subjects and 78,240 control subjects of European ancestry. 8 Subjects were genotyped for 220,231 non-synonymous autosomal variants on the Illumina HumanExome BeadChip v1.0 (Illumina, San Diego, Ca). Quality control filters were applied before and after implementation of a zCall algorithm as described. 9 For variants that passed quality control procedures, individual tests for association with CAD were performed within each study. For variants with a MAF greater than 0% in both cases and controls, logistic regression was run on an additive model with the principal components of ancestry as covariates. Individual studies were combined using an inverse-variance weighted meta-analysis. Variants were functionally annotated as published and than restricted to those with a MAF > 0.01%, leaving 54,003
variants with reported association testing. While 8 studies in the MIGen and CARDIoGRAM
Exome array consortia dataset overlapped completely or partially with the CARDIoGRAMplusC4D meta-analysis, our focus here differs substantively from that of CARDIoGRAMplusC4D given its specific focus on low-frequency variation.
Exome Sequencing Project and Early-Onset Myocardial Infarction (ESP EOMI)
consortium: Details of the National Heart, Lung and Blood Institute's GO exome sequencing project (NHLBI ESP) and the ESP early-onset myocardial infarction (ESP EOMI) study have been published. 10, 11 Briefly, the ESP EOMI was conducted using 4,703 EOMI case subjects and 5,090 control subjects. EOMI cases were defined as individuals who had an MI at age < 50 years for men and at age < 60 years for women. Control subjects were selected from individuals without a history of MI at baseline or whom did not have an MI during follow-up surveillance to a pre-specified age. Initial exome sequencing on subjects from 11 studies was performed at the Broad Institute with sequencing, exome capture, read mapping, variant analysis and quality control as published previously. 11 Follow-up sequencing was subsequently performed on samples from three additional studies. These samples were similarly sequenced at the Broad Institute with processing and quality control as published. 11 To test whether rare mutations contribute to EOMI, burden of rare variant association testing was performed on SNPs and indels present in CCR2, CCR5, and CX3CR1. The analysis was performed using the Efficient
Mixed-Model Association eXpedited (EMMAX) Combined Multivariate and Collapsing (CMC)
test. 12 The analysis was restricted to variants with a MAF < 1% as calculated using all sequenced samples in the study. Variants were analyzed using seven algorithms: LRT score, MutationTaster, PolyPhen-2 HumVar, PolyPhen-2 HumDiv, SIFT, MutationAssessor, and FATHMM. [13] [14] [15] [16] [17] [18] To enrich for harmful alleles, different iterations of rare variant testing were performed using (1) non-synonymous variants; (2) disruptive variants (nonsense, slice-site, and indel frameshift variants); and (3) deleterious variants, defined as disruptive variants in combination with missense variants damaging by five, six, or seven of the aforementioned algorithms. Reported P-values were calculated using the EMMAX CMC test.
The Pakistan Risk of Myocardial Infarction Study (PROMIS): PROMIS is a retrospective
case-control study of acute, first MIs in 6 centers in urban Pakistan combining data from 9,058 subjects with an acute MI and 8,378 control subjects. 19, 20 Cases were defined as subjects presenting within 24 hours of symptom onset with typical ECG changes and a positive troponin-I. Control subjects were drawn from individuals without self-reported cardiovascular disease identified in the same hospitals as index cases. For each participant, information was collected on demographic factors, lifestyle, personal and family history. Non-fasting blood samples were collected from each participant to allow for measurement of serum biomarkers.
Samples were genotyped on the Illumina 660 and Illumina 770 arrays. Genotypes were imputed using the 1000 phase I integrated reference panel (March, 2012) using SHAPEIT and IMPUTE2. [21] [22] [23] SNPs were filtered for HWE <1x10 -5 , imputation quality score (INFO) <0.7, and MAF < 1%. Individual tests for association were performed with respect to MI adjusting for the first four principal components. The genomic inflation factor was 1.09.
Studies of glucometabolic traits:
Diabetes Genetics Replication and Meta-analysis (DIAGRAM): DIAGRAM contains information on 12,171 case subjects with type II Diabetes Mellitus (DM) and 56,862 control subjects of European descent combined across 12 GWAS. The details of the study have been published. 24 Sample and SNP quality control were undertaken within each study. Each GWAS was imputed using the phase II CEU HapMap reference panel. SNPs with a MAF>1% passing quality control criteria were tested for association with type II DM under an additive model after adjustment for study-specific covariates. Association summary statistics were combined via a fixed-effects, inverse-variance weighted meta-analysis.
The Genetic Investigation of ANthropometric Traits (GIANT) consortium:
The GIANT meta-analysis contains genetic information on 123,865 subjects of European ancestry combined from across 46 studies. 25 All samples were genotyped using the Affymetrix (Affymetrix, Santa Clara, Ca) and Illumina (Illumina, San Diego, CA) whole genome genotyping arrays.
Polymorphic SNPs were imputed using the HapMap CEU reference panel.
Association analysis with Body Mass Index (BMI):
The GWAS on BMI includes genetic information from subjects across all 46 studies. 25 Each study performed single marker association analyses with BMI under an additive genetic model. BMI was adjusted for age, age 2 , and principal components as deemed appropriate and than inverse normally transformed. SNPs with poor imputation quality and a minor allele count less than 3 in each sex-and case-specific stratum were excluded. The meta-analysis was performed in METAL using both the inverse variance method and the weighted z-score method.
Association analysis with Waist-Hip Ratio (WHR):
The GWAS on WHR includes information on a subset of 77,167 subjects from 32 GWAS. 26 For each cohort, age-adjusted residuals were calculated for men and women separately with BMI adjustment then inverse normally transformed to ensure comparability across studies. SNP associations for WHR adjusted for BMI were computed by linear regression separately for men and women though these were combined to account for relatedness when appropriate. In addition to study-specific quality control measures, SNPs were excluded for low imputation quality and if the MAF times the number of subjects for a SNP in one study was less than 3. 26 A fixed-effects, inverse-variance weighted model was used to pool β estimates. P-values and standard errors for each study were genomic control corrected and a second genomic control correction was applied to metaanalyzed results.
Global Lipids Genetics Consortium (GLGC):
The 2010 GLGC meta-analysis includes information on 100,184 individuals of European descent from 46 GWAS of lipids and lipidrelated traits. 27 Each study performed genotype imputation with respect to the phase II CEU HapMap reference panel. Residual lipoprotein concentrations were determined after regression adjustment for the covariates age, age 2 , and sex. Each genotyped or imputed SNP was tested for association with each trait assuming an additive genetic model. Linear regression was employed for studies of unrelated individuals and linear mixed effects models were used to account for family structure in family-based studies. SNPs with a MAF < 0.01 and poor imputation quality were excluded. Results were combined using a fixed effects meta-analysis in METAL for each of the lipid traits. 
Meta-Analysis of glucose and Insulin-related traits consortium (MAGIC):
